Navigation Links
PharmaPoint: Dry Eye Syndrome - Current and Future Players
Date:11/6/2013

London (PRWEB) November 06, 2013

Summary

GlobalData has released its pharma report, “PharmaPoint: Dry Eye Syndrome - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing DES Market. The report identifies and analyses the key companies shaping and driving the global DES market. The report provides insight into the competitive DES landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation.

Scope

-Investigation of current and future market competition for DES
-Competitor assessment
-Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
-Strategic assessment of DES sector through market impact analysis, future market scenario and company analysis.

Reasons to buy

-Gain a high level view of the trends shaping and driving DES Market
-Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
-Create an effective counter-strategy to gain a competitive advantage against those currently in the market
-What’s the next big thing in the global DES market landscape? Identify, understand and capitalize.

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
3 Market Outlook 9
3.1 Global Markets 9
3.1.1 Forecast 9
3.1.2 Drivers and Barriers – Global Issues 11
4 Current and Future Players 14
4.1 Overview 14
4.2 Trends in Corporate Strategy 16
4.3 Company Profiles 17
4.3.1 Allergan 17
4.3.2 Alcon (a wholly-owned subsidiary of Novartis AG) 19
4.3.3 Santen Pharmaceutical 22
4.3.4 Shire/SARcode Bioscience 25
4.3.5 Otsuka Holdings 27
4.3.6 Can-Fite Biopharma 29
4.3.7 Eyegate Pharma 30
5 Appendix 32
5.1 Bibliography 32
5.2 Abbreviations 33
5.3 Methodology 34
5.4 Forecasting Methodology 34
5.4.1 Diagnosed DES patients 34
5.4.2 Percent Drug-treated Patients 35
5.4.3 Drugs Included in Each Therapeutic Class 35
5.4.4 Launch and Patent Expiry Dates 35
5.4.5 General Pricing Assumptions 36
5.4.6 Individual Drug Assumptions 37
5.4.7 Generic Erosion 41
5.5 Physicians and Specialists Included in this Study 42
5.6 About the Authors 43
5.6.1 Author 43
5.6.2 Global Head of Healthcare 44
5.7 About GlobalData 45
5.8 Contact Us 45
5.9 Disclaimer 45

1.1 List of Tables

Table 1: Global Sales Forecasts ($m) for Dry Eye Syndrome, 2012–2022 10
Table 2: Dry Eye Syndrome Global Market – Drivers and Barriers, 2012–2022 11
Table 3: Key Companies in the Dry Eye Syndrome Market, 2012 15
Table 4: Allergan’s Dry Eye Syndrome Portfolio Assessment, 2012 18
Table 5: Allergan SWOT Analysis, 2012 19
Table 6: Alcon’s Dry Eye Syndrome Portfolio Assessment, 2012 20
Table 7: Alcon’s Dry Eye Syndrome Portfolio SWOT Assessment, 2012 21
Table 8: Santen Pharmaceutical’s Dry Eye Syndrome Portfolio Assessment, 2012 22
Table 9: Santen Pharmaceutical’s Dry Eye Syndrome Portfolio Assessment, 2012 24
Table 10: Santen Pharmaceutical’s Dry Eye Syndrome Portfolio SWOT Analysis, 2012 25
Table 11: Shire’s Dry Eye Syndrome Portfolio Assessment, 2013 26
Table 12: Shire’s Dry Eye Syndrome Portfolio SWOT Analysis, 2013 26
Table 13: Otsuka Pharmaceutical’s Dry Eye Syndrome Portfolio Assessment, 2012 28
Table 14: Otsuka Pharmaceutical’s Dry Eye Syndrome Portfolio SWOT Analysis, 2012 28
Table 15: Can-Fite Dry Eye Syndrome Portfolio Assessment, 2012 29
Table 16: Can-Fite’s Dry Eye Syndome Portfolio SWOT Analysis, 2012 30
Table 17: Eyegate Pharma’s Dry Eye Syndrome Portfolio Assessment, 2012 31
Table 18: Eyegate Pharma’s Dry Eye Syndrome Portfolio SWOT Analysis, 2012 31
Table 19: Key Launch Dates 35
Table 20: Key Patent Expiries 35
1.2 List of Figures

Figure 1: Global Sales for Dry Eye Syndrome by Region, 2012–2022 11
Figure 2: Company Portfolio Gap Analysis in Dry Eye Syndrome, 2012–2022 16

Companies Mentioned

Allergan
Alcon (a wholly-owned subsidiary of Novartis AG)
Santen Pharmaceutical
Shire/SARcode Bioscience
Otsuka Holdings
Can-Fite Biopharma
Eyegate Pharma

Read the full report:

PharmaPoint: Dry Eye Syndrome - Current and Future Players

http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_dry_eye_syndrome_current_future_players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com/

Read the full story at http://www.prweb.com/releases/2013/11/prweb11307500.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
2. PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022
3. PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022
4. PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022
5. PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022
6. PharmaPoint: Chronic Heart Failure - US Drug Forecast and Market Analysis to 2022
7. PharmaPoint: Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022
8. PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
9. PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players
10. PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022
11. PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to 2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... 2017 , ... The Women’s Choice Award, a growing platform that gives a ... Women’s Choice Award. The identification by women of an effective new migraine relief ... are women. In a survey taken by the Women’s Choice Award organization, nine out ...
(Date:8/22/2017)... ... 2017 , ... Pivot Point Consulting, a ... the firm’s new Consulting Services Executive. Mr. Tisch will oversee all aspects of ... clients with initial vendor selection and pre-implementation planning through go-live support and post-live ...
(Date:8/22/2017)... ... , ... Nurses at Apple Rehab Watch Hill , a nursing and ... certification in Closed Pulse Irrigation™ (CPI) for wound care. This qualifies ... for Medicare and Medicaid Services, to have a CPI machine that will provide better ...
(Date:8/22/2017)... ... ... “Wilderness Voices”: a collection of poetry inspired by life on a Kentucky ... published author, Martha McKown, an ordained United Methodist minister with graduate degrees in Religious ... her older sisters studied High School literature. She loved the early English folk ...
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery ... published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent ... shares, “Love is one of the least understood and yet most sought-after pleasures known ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Fenita J. Caldwell is ... Lifetime Professional in the Field of Healthcare. Caldwell ... Pharmaceuticals, AG. Her skills and areas of expertise ... Fenita ... experience as a highly successful sales specialist in ...
(Date:8/2/2017)... 2017  Life Flight Network and PeaceHealth Oregon Network announced ... care and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Life Flight Network work collaboratively to move patients who require ... a time sensitive emergency exists. ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
Breaking Medicine Technology: